-21.7%
MRNA vs GSK
+42.7%
-64.4%
-93.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.8% | -1.3% | -3.5% | -3.8% |
| 7D | -20.9% | -3.1% | -17.7% | -18.9% |
| 30D | -13.3% | -0.9% | -12.4% | -12.9% |
| 3M | +212.6% | -4.2% | +216.7% | +229.0% |
| 6M | +309.0% | -1.6% | +310.6% | +323.3% |
| YTD | +567.3% | +2.6% | +564.7% | +571.7% |
| 1Y | +689.7% | +6.2% | +683.5% | +681.1% |
| 3Y | +157.4% | +55.0% | +102.5% | +109.6% |
| 5Y | -21.7% | +42.8% | -64.6% | -19.6% |
| All | -21.7% | +42.7% | -64.4% | -19.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling